• Home
  • News and Stories
  • Community Corner: New Drug Indications Expand Options For People With Epilepsy

Community Corner: New Drug Indications Expand Options for People with Epilepsy

Community Corner
  • The FDA has approved a new process where data about a medicine's use for adults or as an add-on therapy can be reviewed to determine if it can be extrapolated (extended) for use in children or alone.
  • Through extrapolation, new uses have been approved for lacosamide and eslicarbazepine acetate in children, as well as brivaracetam as a monotherapy (given alone) for adults.

Epilepsy News From: Monday, November 13, 2017

In recent months, the U.S. Food and Drug Administration (FDA) has approved important changes to indications for three anti-seizure medications.

New Approvals in Children

Vimpat® (lacosamide)

Last week, the FDA approved an important change to the use of lacosamide. This change allows a liquid form of lacosamide, known as Vimpat CV (from UCB), to be prescribed for children age 4 years and older who have focal or partial onset seizures. It is approved for use as monotherapy (given alone) or as an add-on drug (given together with another seizure medication).

For information about dosing and use of lacosamide in children, please read the Vimpat medication guide.

This indication is based on a new process approved by the FDA to evaluate data about the benefits of lacosamide in adults and extrapolate (extend) this to children. Studies were also done on the medicine’s safety and how a child’s body handles the drug (pharmacokinetics). This information is important for clinicians to safely prescribe lacosamide to children.

Aptiom® (eslicarbazepine acetate)

In September 2017, the FDA expanded the use of Aptiom (from Sunovion) to treat focal or partial seizures in children 4 to 17 years old. Aptiom is already approved for use in adults with focal onset seizures. The information from adults as well as other studies on safety and use of Aptiom in children led to extending the use of this medicine to children and adolescents.

For information about dosing and use of eslicarbazepine acetate, see the Aptiom prescribing information.

New Approvals in Monotherapy

Briviact® CV (brivaracetam)

Briviact CV was approved in September 2017 for use as monotherapy (given alone) in people 16 years of age and older with focal or partial onset seizures. Briviact (from UCB) is already approved for use as an add-on treatment, which means it is given in addition to another seizure medicine. This indication is based on a new process approved by the FDA. Data about the medicine used as an add-on therapy is reviewed to determine if it can be extrapolated (extended) so the medicine can be given alone. This allows more flexible options for adults with focal seizures.

For information about dosing and use of brivaracetam, see the Briviact prescribing information.

Summary

The ability to extrapolate (extend) data from one type of use to another is a critical advancement in epilepsy drug research. As previously reported, medicines no longer have to be studied specifically in children or alone to be approved for those uses if the adult or add-on data provides enough information. This helps get safe and effective seizure medicines to peope who need them quicker. Facilitating the approval of seizure medicines for use alone, instead of add-on therapy, offers safer alternatives to people who may have more side effects when given more than one medicine at a time.

Learn More

Reviewed by

Barry Gidal, PharmD

Reviewed Date

Monday, November 13, 2017

Sign Up for Emails

Stay up to date with the latest epilepsy news, stories from the community, and more.